BioCentury
ARTICLE | Clinical News

Roche scraps taselisib plans based on ASCO data

June 8, 2018 3:14 PM UTC

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit said they will not seek approval for taselisib after the Phase III SANDPIPER study to treat metastatic breast cancer showed that the molecule provided limited benefit. However, they aren’t giving up on the pathway targeted by the molecule -- phosphoinositide 3-kinase (PI3K).

The double-blind, international SANDPIPER trial enrolled 516 postmenopausal women with locally advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer harboring a PI3K catalytic subunit alpha polypeptide (PI3KCA; p110alpha) gene mutation and who relapsed after treatment with an aromatase inhibitor. Taselisib is a PI3K alpha inhibitor...